Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Transplantation of pancreatic islets for the treatment of type 1 diabetes allows for physiologic glycemic control and insulin-independence when sufficient islets are implanted via the portal vein into the liver. Intrahepatic islet implantation requires specific infrastructure and expertise, and risks inherent to the procedure include bleeding, thrombosis, and elevation of portal pressure. Additionally, the relatively higher drug metabolite concentrations in the liver may contribute to the delayed loss of graft function of recent clinical trials. Identification of alternative implantation sites using biocompatible devices may be of assistance improving graft outcome. A desirable bioartificial pancreas should be easy to implant, biopsy, and retrieve, while allowing for sustained graft function. The subcutaneous (SC) site may require a minimally invasive procedure performed under local anesthesia, but its use has been hampered so far by lack of early vascularization, induction of local inflammation, and mechanical stress on the graft. METHODS: Chemically diabetic rats received syngeneic islets into the liver or SC into a novel biocompatible device consisting of a cylindrical stainless-steel mesh. The device was implanted 40 days prior to islet transplantation to allow embedding by connective tissue and neovascularization. Reversal of diabetes and glycemic control was monitored after islet transplantation. RESULTS: Syngeneic islets transplanted into a SC, neovascularized device restored euglycemia and sustained function long-term. Removal of graft-bearing devices resulted in hyperglycemia. Explanted grafts showed preserved islets and intense vascular networks. CONCLUSIONS: Ease of implantation, biocompatibility, and ability to maintain long-term graft function support the potential of our implantable device for cellular-based reparative therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-Up After Clinical Islet Transplantation
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2060 · Cited by 1,641
Cited by
Advances in islet encapsulation technologies
Desai, T., & Shea, L. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.232 · Cited by 427
Pedraza, E., Coronel, M. M., Fraker, C. A., Ricordi, C., & Stabler, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113560109 · Cited by 399
Self-citationA prevascularized subcutaneous device-less site for islet and cellular transplantation
Pepper, A. R., Gala-Lopez, B., Pawlick, R., Merani, S., Kin, T., & Shapiro, A. M. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3211 · Cited by 381
Optimal implantation site for pancreatic islet transplantation
Merani, S., Toso, C., Emamaullee, J., & Shapiro, A. M. J. (2008) · British Journal of Surgery · doi:10.1002/bjs.6391 · Cited by 257
Weaver, J. D., Headen, D. M., Aquart, J., Johnson, C. T., Shea, L. D., Shirwan, H., & García, A. J. (2017) · Science Advances · doi:10.1126/sciadv.1700184 · Cited by 170
Metadata
- Authors
- Pileggi, A., Molano, R. D., Ricordi, C., Zahr, E., Collins, J., Valdes, R., & Inverardi, L.
- Venue
- Transplantation
- Published
- 2006-05-15
- Volume
- 81
- Issue
- 9
- Pages
- 1318-1324
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2093901861
- Cited by
- 181
- References
- 1
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device. https://app.cochat.ai/papers/10.1097/01.tp.0000203858.41105.88
- The paper
- Pileggi, A., Molano, R. D., Ricordi, C., Zahr, E., Collins, J., Valdes, R., & Inverardi, L. (2006). Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device. Transplantation. https://doi.org/10.1097/01.tp.0000203858.41105.88
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.